← Leaderboards
Ralph A Defronzo
University Of Texas Hlth Sci Ctr San Ant
$27,122,787
Attributed
$31,193,436
Total exposure
57
Grants
32
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,317,642 · 57
VA$0 · 1
By mechanism
R01$21,427,533 · 4
U19$12,124,206 · 1
M01$5,928,729 · 49
U01$2,770,051 · 1
R44$994,123 · 1
R56$73,000 · 1
Top collaborators
- John Blangero5 shared
- Geoffrey David Clarke5 shared
- Laura A Cox5 shared
- Ravindranath Duggirala5 shared
- Peter Thornton Fox5 shared
- Donna M Lehman5 shared
- Cun Li5 shared
- Peter W Nathanielsz5 shared
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Lawrence J Mandarino$19,789,957
Others in their field
Top investigators on “Insulin”
- Jeffrey P Krischer · University Of South Florida$605,714,892
- John M Lachin · George Washington University$153,440,346
- David M Nathan · Massachusetts Institute Of Technology$139,041,931
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Mark A Magnuson · Vanderbilt University$79,749,111
- Jose A Luchsinger · Columbia University Health Sciences$71,267,462
Research focus
InsulinGlucose MetabolismHuman SubjectClinical ResearchGlucoseNoninsulin Dependent Diabetes MellitusGrantPlasmaHyperglycemiaDiabetes MellitusMetabolicGlucose TransportMuscleInfusion ProceduresInsulin ResistanceBiopsyHepaticObesityNon-Insulin-Dependent Diabetes MellitusUnited States National Institutes Of HealthMuscle MetabolismPharmaceutical PreparationsAffectInsulin Sensitivity /Resistance
Grant awards (140)
Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers$682,154
R01 · FY2025 · DK
SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis$674,244
R01 · FY2025 · DK · contact PI
Ketones, Muscle Metabolism, and SGLT2 Inhibitors$582,600
R01 · FY2025 · DK · contact PI
Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers$654,870
R01 · FY2024 · DK
SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis$647,274
R01 · FY2024 · DK · contact PI
Ketones, Muscle Metabolism, and SGLT2 Inhibitors$621,441
R01 · FY2024 · DK · contact PI
Ketones, Muscle Metabolism, and SGLT2 Inhibitors$25,884
R01 · FY2024 · DK · contact PI
Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers$682,158
R01 · FY2023 · DK
SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis$674,244
R01 · FY2023 · DK · contact PI
Ketones, Muscle Metabolism, and SGLT2 Inhibitors$647,334
R01 · FY2023 · DK · contact PI
Ketones, Muscle Metabolism, and SGLT2 Inhibitors$62,119
R01 · FY2023 · DK · contact PI
Womb to Tomb: Developmental Programming and Aging Interactions in Primates$1,505,456
U19 · FY2022 · AG
Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers$695,911
R01 · FY2022 · DK
Ketones, Muscle Metabolism, and SGLT2 Inhibitors$661,084
R01 · FY2022 · DK · contact PI
Ketones, Muscle Metabolism, and SGLT2 Inhibitors$36,235
R01 · FY2022 · DK · contact PI
Womb to Tomb: Developmental Programming and Aging Interactions in Primates$2,638,712
U19 · FY2021 · AG
PRESERVATION OF BETA CELL FUNCTION IN PREDIABETES: IGT AND IFG$663,044
R01 · FY2021 · DK · contact PI
Womb to Tomb: Developmental Programming and Aging Interactions in Primates$2,657,007
U19 · FY2020 · AG
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production$513,780
R01 · FY2020 · DK · contact PI
Womb to Tomb: Developmental Programming and Aging Interactions in Primates$2,644,335
U19 · FY2019 · AG
PRESERVATION OF BETA CELL FUNCTION IN PREDIABETES: IGT AND IFG$663,044
R01 · FY2019 · DK · contact PI
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production$527,165
R01 · FY2019 · DK · contact PI
Discovery of Functional Variants in Type 2 Diabetes Genes in Mexican Americans$322,775
U01 · FY2019 · DK
Womb to Tomb: Developmental Programming and Aging Interactions in Primates$2,678,696
U19 · FY2018 · AG
PRESERVATION OF BETA CELL FUNCTION IN PREDIABETES: IGT AND IFG$663,044
R01 · FY2018 · DK · contact PI
Discovery of Functional Variants in Type 2 Diabetes Genes in Mexican Americans$583,186
U01 · FY2018 · DK
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production$527,165
R01 · FY2018 · DK · contact PI
PRESERVATION OF BETA CELL FUNCTION IN PREDIABETES: IGT AND IFG$652,096
R01 · FY2017 · DK · contact PI
Discovery of Functional Variants in Type 2 Diabetes Genes in Mexican Americans$565,032
U01 · FY2017 · DK
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production$513,574
R01 · FY2017 · DK · contact PI
Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DM$488,805
R01 · FY2017 · DK · contact PI
Discovery of Functional Variants in Type 2 Diabetes Genes in Mexican Americans$565,032
U01 · FY2016 · DK
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production$525,272
R01 · FY2016 · DK · contact PI
Regulation of Hepatic and Peripheral Glucose Metabolism$522,333
R01 · FY2016 · DK · contact PI
Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DM$488,805
R01 · FY2016 · DK · contact PI
SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION$0
I01 · FY2016 · VA · contact PI
Discovery of Functional Variants in Type 2 Diabetes Genes in Mexican Americans$734,026
U01 · FY2015 · DK
Regulation of Hepatic and Peripheral Glucose Metabolism$519,120
R01 · FY2015 · DK · contact PI
Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DM$479,984
R01 · FY2015 · DK · contact PI
Regulation of Hepatic and Peripheral Glucose Metabolism$522,333
R01 · FY2014 · DK · contact PI
Regulation of Hepatic and Peripheral Glucose Metabolism$504,051
R01 · FY2013 · DK · contact PI
Improved Hypoglycemia Rescue Device$576,491
R44 · FY2012 · DK
Regulation of Hepatic and Peripheral Glucose Metabolism$532,778
R01 · FY2012 · DK · contact PI
Improved Hypoglycemia Rescue Device$417,632
R44 · FY2011 · DK
Regulation of Hepatic and Peripheral Glucose Metabolism$479,485
R01 · FY2010 · DK · contact PI
Regulation of Hepatic and Peripheral Glucose Metabolism$99,000
R01 · FY2010 · DK · contact PI
Regulation of Hepatic and Peripheral Glucose Metabolism$484,329
R01 · FY2009 · DK · contact PI
Regulation of Hepatic and Peripheral Glucose Metabolism$481,457
R01 · FY2008 · DK · contact PI
GLYCEMIC CONTROL AND COMPLICATIONS IN DIABETES MELLITUS TYPE 2$14,208
M01 · FY2008 · RR · contact PI
MECHANISMS OF ACTION OF EXUBERA TO NORMALIZE FASTING PLASMA GLUCOSE IN T2DM$5,324
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: EFFECTS OF 8 WKS TRTMT OF VILDAGLIPTIN,EXENATIDE, OR COMBINATION$4,051
M01 · FY2008 · RR · contact PI
MECHANISM OF INSULIN SENSITIZING EFFECT OF PIOGLITAZONE-ROLE OF ADIPONECTIN$2,923
M01 · FY2008 · RR · contact PI
REACTIVE OXYGEN SPECIES (ROS), MITOCHONDRIAL DYSFUNCTION AND T2D (PROT 1)$2,344
M01 · FY2008 · RR · contact PI
MOLECULAR EPIDEMIOLOGY OF TYPE 2 DIABETES MELLITUS IN MEXICAN AMERICANS$2,112
M01 · FY2008 · RR · contact PI
EFFECT OF ACUTE ELEVATION OF FFA ON MITOCHONDRIAL FUNCTION IN SKELETAL MUSCLE$926
M01 · FY2008 · RR · contact PI
PROT 1: EFFECT OF PHYSIOLOGIC INCREASE IN FFA ON MITOCHONDRIAL FUNC IN NGT SUBJ$839
M01 · FY2008 · RR · contact PI
IS NON-DIABETIC FASTING HYPERGLYCEMIA EXPLAINED BY IMPAIRED GLUCOSE UPTAKE$637
M01 · FY2008 · RR · contact PI
PROTOCOL V: EFFECT OF CHRONICALLY ELEVATED PLASMA FFA ON HGP AND GLUCONEOGENESIS$58
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A DOUBLE-BLIND STUDY TO EXPLORE EFFECTS OF LAF237 ON GLUCOSE DUR$48
M01 · FY2008 · RR · contact PI
Regulation of Hepatic and Peripheral Glucose Metabolism$494,213
R01 · FY2007 · DK · contact PI
GLYCEMIC CONTROL AND COMPLICATIONS IN DIABETES MELLITUS TYPE 2$218,188
M01 · FY2007 · RR · contact PI
MECHANISM OF INSULIN SENSITIZING EFFECT OF PIOGLITAZONE-ROLE OF ADIPONECTIN$73,561
M01 · FY2007 · RR · contact PI
MOLECULAR EPIDEMIOLOGY OF TYPE 2 DIABETES MELLITUS IN MEXICAN AMERICANS$65,665
M01 · FY2007 · RR · contact PI
EFFECT OF ACUTE ELEVATION OF FFA ON MITOCHONDRIAL FUNCTION IN SKELETAL MUSCLE$21,611
M01 · FY2007 · RR · contact PI
PROTOCOL V: EFFECT OF CHRONICALLY ELEVATED PLASMA FFA ON HGP & GLUCONEOGENESIS$14,546
M01 · FY2007 · RR · contact PI
EFFECTS OF 8 WKS TRTMT OF VILDAGLIPTIN,EXENAIDE, OR COMBINATION IN PATIENT W/T2D$6,649
M01 · FY2007 · RR · contact PI
REACTIVE OXYGEN SPECIES (ROS), MITOCHONDRIAL DYSFUNCTION AND TYPE 2 DIABETES$6,234
M01 · FY2007 · RR · contact PI
MOLECULAR EPI OF T2DM IN MAS: PROTOCOL 1: EXPANSION OF VAGES FAMILIES$3,740
M01 · FY2007 · RR · contact PI
Regulation of Hepatic and Peripheral Glucose Metabolism$505,956
R01 · FY2006 · DK · contact PI
GLYCEMIC CONTROL AND COMPLICATIONS IN DIABETES MELLITUS TYPE 2$248,415
M01 · FY2006 · RR · contact PI
MOLECULAR EPIDEMIOLOGY OF TYPE 2 DIABETES MELLITUS IN MEXICAN AMERICANS$94,103
M01 · FY2006 · RR · contact PI
PROT V: EFFECT OF CHRONICALLY ELEVATED PLASMA FFA ON HGP AND GLUCONEOGENESIS$90,089
M01 · FY2006 · RR · contact PI
REACTIVE OXYGEN SPECIES (ROS), MITOCHONDRIAL DYSFUNCTION AND TYPE 2 DIABETES$36,125
M01 · FY2006 · RR · contact PI
A DOUBLE-BLIND STUDY TO EXPLORE EFFECTS OF LAF237 ON GLUCOSE DURING OVERNIGHT$30,773
M01 · FY2006 · RR · contact PI
ROLE OF SERINE PHOS IN INSULIN RESISTANCE IN VIVO IN HUMAN MUSCLE (NIH PROT 2A)$10,704
M01 · FY2006 · RR · contact PI
MECHANISM OF INSULIN SENSITIZING EFFECT OF PIOGLITAZONE-ROLE OF ADIPONECTIN$5,797
M01 · FY2006 · RR · contact PI
ACTOS NOW FOR PREVENTION OF DIABETES (ACT NOW)$4,906
M01 · FY2006 · RR · contact PI
MOLECULAR EPI OF T2DM IN MAS: PROTOCOL 1: EXPANSION OF VAGES FAMILIES$892
M01 · FY2006 · RR · contact PI
GLYCEMIC CONTROL AND COMPLICATIONS IN DIABETES MELLITUS TYPE 2$315,346
M01 · FY2005 · RR
PROT V: EFFECT OF CHRONICALLY ELEVATED PLASMA FFA ON HGP AND GLUCONEOGENESIS$145,213
M01 · FY2005 · RR
Regulation of Hepatic and Peripheral Glucose Metabolism$73,000
R56 · FY2005 · DK
EFFECT OF PIOGLITAZONE ON INSULIN SIGNALING AND MUSCLE FAT CONTENT$63,261
M01 · FY2005 · RR
A DOUBLE-BLIND STUDY TO EXPLORE EFFECTS OF LAF237 ON GLUCOSE DURING OVERNIGHT$41,216
M01 · FY2005 · RR
PIOGLITAZONE SPLANCHNIC GLUC UPTAKE, HEPATIC GLUC PROD, INS SENST, MSCL FAT CONT$19,170
M01 · FY2005 · RR
MOLECULAR EPIDEMIOLOGY OF TYPE 2 DIABETES MELLITUS IN MEXICAN AMERICANS$18,212
M01 · FY2005 · RR
REGULATION OF HEPATIC AND PERIPHERAL GLUCOSE METABOLISM$574,035
R01 · FY2004 · DK
Glycemic Control and Complications in NIDDM$348,412
M01 · FY2004 · RR
Pioglitazone--Insulin Signaling and Muscle Fat in PCOS$69,393
M01 · FY2004 · RR
Reduction in Plasma FFA Concentration with Fenofilbrate$66,864
M01 · FY2004 · RR
Fenofibrate--Glucose/Lipid Metab in NIDDM &Insul sense$63,972
M01 · FY2004 · RR
Chronically Elevated Plasma FFA on HGP &Gluconeogenesis$59,635
M01 · FY2004 · RR
Effect of Acipimox on Glucose Metabolism in NIDDM$45,178
M01 · FY2004 · RR
Pioglitazone Splanchnic Gluc Uptake, Hepatic Gluc Prod, Ins Senst, Mscl Fat Cont$35,058
M01 · FY2004 · RR
Molecular Epidemiology of NIDDM in Mexican Americans$27,830
M01 · FY2004 · RR
Reduction of Hyprinsulinemia--Glucose Metab/insul Sense$21,685
M01 · FY2004 · RR
Nitric Oxide, Endothelial Dysfunction &Type 2 Diabetes$1,807
M01 · FY2004 · RR
REGULATION OF HEPATIC AND PERIPHERAL GLUCOSE METABOLISM$561,280
R01 · FY2003 · DK
REGULATION OF HEPATIC AND PERIPHERAL GLUCOSE METABOLISM$549,359
R01 · FY2002 · DK
MOLECULAR EPIDEMIOLOGY OF TYPE 2 DIABETES IN MEXICAN AMERICANS$234,837
M01 · FY2002 · RR
EFFECT OF PROLONGED REDUCTION OF HYPERINSULINEMIA ON GLUCOSE METABOLISM$234,837
M01 · FY2002 · RR
EFFECT OF PROLONGED REDUCTION OF HYPERINSULINEMIA ON GLUCOSE METABOLISM$234,837
M01 · FY2002 · RR
EFFECT OF TIGHT GLYCEMIC CONTROL ON GLUCOSE PHOSPHORYLATION &TRANSPORT$234,837
M01 · FY2002 · RR
EFFECT OF TIGHT GLYCEMIC CONTROL ON GLUCOSE PHOSPHORYLATION &TRANSPORT$234,837
M01 · FY2002 · RR
ACUTE EFFECT OF PHLORIZIN ON PLASMA GLUCOSE LEVELS &HEPATIC GLUCOSE$234,837
M01 · FY2002 · RR
ACUTE EFFECT OF PHLORIZIN ON PLASMA GLUCOSE LEVELS &HEPATIC GLUCOSE$234,837
M01 · FY2002 · RR
MOLECULAR EPIDEMIOLOGY OF TYPE 2 DIABETES IN MEXICAN AMERICANS$234,837
M01 · FY2002 · RR
INSULIN EFFECTS ON GLUCOSE TRANSPORTERS OF HUMAN PERIPHERAL TISSUE$234,837
M01 · FY2002 · RR
INSULIN EFFECTS ON GLUCOSE TRANSPORTERS OF HUMAN PERIPHERAL TISSUE$234,837
M01 · FY2002 · RR
GLYCOLYSIS IN INSULIN MEDIATED GLUCOSE DISPOSAL$0
M01 · FY2002 · RR
HYPERINSULINEMIA--GLUCOSE PHOSPHORYLATION/TRANSPORT$0
M01 · FY2002 · RR
HYPERINSULINEMIA--GLUCOSE PHOSPHORYLATION/TRANSPORT$0
M01 · FY2002 · RR
LIVER ACTION IN GLUCOSE HOMEOSTASIS IN DIABETICS/NORMALS$0
M01 · FY2002 · RR
LIVER ACTION IN GLUCOSE HOMEOSTASIS IN DIABETICS/NORMALS$0
M01 · FY2002 · RR
IGF1 EFFECT ON LIPID/FFA METABOLISM--PROTOCOL VI$0
M01 · FY2002 · RR
IGF1 EFFECT ON LIPID/FFA METABOLISM--PROTOCOL VI$0
M01 · FY2002 · RR
IGF1 ON MUSCLE GLUCOSE PHOSPHORYLATION AND TRANSPORT$0
M01 · FY2002 · RR
IGF1 ON MUSCLE GLUCOSE PHOSPHORYLATION AND TRANSPORT$0
M01 · FY2002 · RR
GLYCOLYSIS IN INSULIN MEDIATED GLUCOSE DISPOSAL$0
M01 · FY2002 · RR
REGULATION OF HEPATIC AND PERIPHERAL GLUCOSE METABOLISM$544,474
R01 · FY2001 · DK
INSULIN EFFECTS ON GLUCOSE TRANSPORTERS OF HUMAN PERIPHERAL TISSUE$234,837
M01 · FY2001 · RR
EFFECT OF PROLONGED REDUCTION OF HYPERINSULINEMIA ON GLUCOSE METABOLISM$234,837
M01 · FY2001 · RR
EFFECT OF TIGHT GLYCEMIC CONTROL ON GLUCOSE PHOSPHORYLATION &TRANSPORT$234,837
M01 · FY2001 · RR
ACUTE EFFECT OF PHLORIZIN ON PLASMA GLUCOSE LEVELS &HEPATIC GLUCOSE$234,837
M01 · FY2001 · RR
MOLECULAR EPIDEMIOLOGY OF TYPE 2 DIABETES IN MEXICAN AMERICANS$234,837
M01 · FY2001 · RR
GLYCOLYSIS IN INSULIN MEDIATED GLUCOSE DISPOSAL$0
M01 · FY2001 · RR
HYPERINSULINEMIA--GLUCOSE PHOSPHORYLATION/TRANSPORT$0
M01 · FY2001 · RR
LIVER ACTION IN GLUCOSE HOMEOSTASIS IN DIABETICS/NORMALS$0
M01 · FY2001 · RR
IGF1 EFFECT ON LIPID/FFA METABOLISM--PROTOCOL VI$0
M01 · FY2001 · RR
IGF1 ON MUSCLE GLUCOSE PHOSPHORYLATION AND TRANSPORT$0
M01 · FY2001 · RR
MOLECULAR EPIDEMIOLOGY OF TYPE 2 DIABETES IN MEXICAN AMERICANS$16,409
M01 · FY2000 · RR
EFFECT OF PROLONGED REDUCTION OF HYPERINSULINEMIA ON GLUCOSE METABOLISM$16,409
M01 · FY2000 · RR
EFFECT OF TIGHT GLYCEMIC CONTROL ON GLUCOSE PHOSPHORYLATION &TRANSPORT$16,409
M01 · FY2000 · RR
ACUTE EFFECT OF PHLORIZIN ON PLASMA GLUCOSE LEVELS &HEPATIC GLUCOSE$16,409
M01 · FY2000 · RR
INSULIN EFFECTS ON GLUCOSE TRANSPORTERS OF HUMAN PERIPHERAL TISSUE$16,409
M01 · FY2000 · RR
EFFECT OF CHRONIC HYPERINSULINEMIA ON GLUCOSE PHOSPHORYLATION AND TRANSPORT$16,409
M01 · FY2000 · RR
HYPERINSULINEMIA--GLUCOSE PHOSPHORYLATION/TRANSPORT$0
M01 · FY2000 · RR
LIVER ACTION IN GLUCOSE HOMEOSTASIS IN DIABETICS/NORMALS$0
M01 · FY2000 · RR
IGF1 EFFECT ON LIPID/FFA METABOLISM--PROTOCOL VI$0
M01 · FY2000 · RR
IGF1 ON MUSCLE GLUCOSE PHOSPHORYLATION AND TRANSPORT$0
M01 · FY2000 · RR
GLYCOLYSIS IN INSULIN MEDIATED GLUCOSE DISPOSAL$0
M01 · FY2000 · RR